

Contents

| Title | Content | Pg.No. |
|--------------------|--|----------|
| | Declaration by Research Scholar–Originality of Research Work | I |
| | Certificate of Supervisor | II |
| | Thesis Approval Form | III |
| | Declaration by Research Scholar – Submission of Thesis | IV |
| | Acknowledgment | V |
| | Contents | VI |
| | List of Figures | XIV |
| | List of Tables | XVIII |
| | List of Abbreviation and symbol | XXI |
| | Abstract | XXV |
| Chapter : 1 | Introduction | 1 |
| | 1.1 Introduction | 1 |
| | 1.2 Epidemiology | 3 |
| | 1.3 Etiology | 5 |
| | 1.3.1 Inherited or genetic factors | |
| | 1.3.2 Acquired factors | |
| | 1.3.3 Environmental factors | |
| | 1.4 Thrombotic Disease and its Alternative Herbal Treatment | 5 |
| Chapter : 2 | Review of Literature | 9 |
| | 2.1 Introduction | 9 |
| | 2.2 The Coagulation Cascade | 9 |
| | 2.3 Thrombus formation | 10 |
| | 2.4 Virchow's Triad | 11 |
| | 2.5 Types of Thrombi | 12 |
| | 2.5.1 Arterial thrombi | 12 |
| | 2.5.2 Venous thrombi | 13 |
| | 2.5.2.1 Venous thromboembolism | 13 |
| | 2.6 Treatment | 15 |
| | 2.7 Review of Literature of <i>Tecomella undulata</i> | 15 |
| | 2.7.1 Habitat | 16 |
| | 2.7.2 Vernacular Name | 16 |

| | | |
|--------------------|--|-----------|
| 2.7.3 | Synonym | 16 |
| 2.7.4 | Trade Name | 16 |
| 2.7.5 | Scientific Classification | 16 |
| 2.7.6 | Description | 16 |
| 2.7.7 | Phytochemical Review of <i>Tecomella undulata</i> | 17 |
| 2.7.8 | Pharmacological Review of <i>Tecomella undulata</i> | 19 |
| 2.8 | Review of Literature of <i>Citrus medica</i> | 21 |
| 2.8.1 | Habitat | 21 |
| 2.8.2 | Vernacular Name | 21 |
| 2.8.3 | Scientific Classification | 21 |
| 2.8.4 | Description | 22 |
| 2.8.5 | Phytochemical Review of <i>Citrus medica</i> | 23 |
| 2.8.6 | Pharmacological Review of <i>Citrus medica</i> | 26 |
| 2.9 | Review of Literature of <i>Sesame indicum</i> | 28 |
| 2.9.1 | Vernacular Name | 28 |
| 2.9.2 | Scientific Classification | 28 |
| 2.9.3 | Description | 29 |
| 2.9.4 | Phytochemical Review of <i>Sesame indicum</i> | 30 |
| 2.9.5 | Pharmacological Review of <i>Sesame indicum</i> | 32 |
| 2.10 | Latest Discoveries of Plants with Anticoagulant Properties | 34 |
| Chapter : 3 | Aim and Objective | 36 |
| 3.1 | Rational | 36 |
| 3.2 | Aim | 36 |
| 3.3 | Objective | 36 |
| Chapter : 4 | Material and Method | 38 |
| 4.1 | Plant collection and authentication | 38 |
| 4.2 | Extraction Method | 39 |
| 4.3 | Preliminary phytochemical screening of crude extracts | 39 |
| 4.3.1 | Material | 39 |
| 4.3.2 | Preliminary phytochemical screening | 39 |
| 4.4 | Phytochemical Analysis of Crude Extract | 43 |
| 4.4.1 | Ash Values | 43 |
| 4.4.2 | Extractive values | 44 |

| | |
|--|----|
| 4.4.3 Determination of moisture content | 45 |
| 4.4.4 Determination of foreign matter | 45 |
| 4.4.5 Foaming index | 46 |
| 4.4.6 Determination of swelling index | 46 |
| 4.4.7 Determination of Solvent Residue | 47 |
| 4.4.7.1 Sample Preparation | 47 |
| 4.4.7.2 Parameters of GC-MS and Headspace for Solvent | 47 |
| Residue Analysis | |
| 4.5 Determination of Total phenolic content of crude extract | 49 |
| 4.6 Determination of Total Flavonoid Content of crude extract | 49 |
| 4.7 Determination of Total Antioxidant Activity (TAC) of crude extract | 50 |
| 4.8 <i>In-vitro</i> anticoagulant activity of crude extracts | 51 |
| 4.8.1 Experimental animals | 51 |
| 4.8.2 Acute Toxicity | 51 |
| 4.8.3 Blood sampling and plasma preparation | 51 |
| 4.8.4 Blood clotting time measurement | 52 |
| 4.8.5 Prothrombin time (PT) activity assay | 52 |
| 4.8.6 Activated Partial Thromboplastin time (APTT) activity assay | 52 |
| 4.8.7 Statistical Analysis | 53 |
| 4.9 Preparation of fractions | 53 |
| 4.10 Preliminary phytochemical screening of fractions | 54 |
| 4.10.1 Material | 54 |
| 4.10.2 Preliminary phytochemical screening | 54 |
| 4.11 Phytochemical Analysis of Fractions | 54 |
| 4.12 Determination of Total phenolic content of Fractions | 54 |
| 4.13 Determination of Total Flavonoid Content of Fractions | 54 |
| 4.14 Determination of Total Antioxidant Activity (TAC) of Fractions | 54 |
| 4.15 <i>In-vitro</i> antioxidant activity of fractions of potent crude extract of the plant | 55 |
| 4.15.1 DPPH Radical scavenging activity | 55 |

| | |
|--|----|
| 4.15.2 Superoxide radical scavenging activity | 55 |
| 4.15.3 Nitric oxide radical scavenging activity | 56 |
| 4.15.4 Metal ion chelating activity | 57 |
| 4.15.5 Reducing power | 58 |
| 4.16 Qualitative HPTLC Fingerprinting | 59 |
| 4.16.1 Selection of plate and adsorbent | 59 |
| 4.16.2 Preparation of sample solutions | 59 |
| 4.16.3 Application of samples | 59 |
| 4.16.4 Solvent system | 60 |
| 4.16.5 Optimization of Chromatographic Condition | 60 |
| 4.16.6 Detection | 60 |
| 4.16.7 Evaluation of TLC plate | 60 |
| 4.16.8 Interpretation of HPTLC chromatograph | 60 |
| 4.17 <i>In-vitro</i> anticoagulant activity of fractions | 61 |
| 4.17.1 Experimental animals | 61 |
| 4.17.2 Blood sampling and plasma preparation | 61 |
| 4.17.3 Blood clotting time measurement | 62 |
| 4.17.4 Prothrombin time (PT) activity assay | 62 |
| 4.17.5 Activated Partial Thromboplastin time (APTT) activity assay | 62 |
| 4.17.6 Statistical Analysis | 62 |
| 4.18 <i>In-vivo</i> anticoagulant activity of fractions | 63 |
| 4.18.1 Experimental animals | 63 |
| 4.18.2 Experimental Design | 63 |
| 4.18.3 Blood sampling collection and plasma preparation | 64 |
| 4.18.4 Statistical Analysis | 64 |
| 4.19 GCMS Analysis | 64 |
| 4.19.1 Preparation of the fraction | 64 |
| 4.19.2 Parameters of GC-MS Analysis | 64 |
| 4.19.3 Optimization parameter of GC-MS analysis Conditions | 65 |
| 4.19.4 Identification of Components | 66 |
| 4.20 LCMS/MS Analysis | 66 |
| 4.20.1 Preparation of the fraction | 66 |

| | | |
|--------------------|--|-----------|
| 4.20.2 | Preparation of Standard Stock Solution | 66 |
| 4.20.3 | Mix Drug intermediate Solution (100µg/mL of each standard) | 67 |
| 4.20.4 | Solvent system | 67 |
| 4.20.5 | Auto Sampler Rinsing Solution | 67 |
| 4.20.6 | Calibration Curve (CC) Spiking Solutions | 67 |
| 4.20.7 | LC-MS/MS instrumentation and Chromatographic condition | 68 |
| 4.20.8 | Determination of Selected Polyphenolic Compounds in Fractions | 70 |
| 4.21 | Isolation and Characterization of Bioactive Compound from ethyl acetate fraction of <i>Citrus medica</i> | 71 |
| 4.21.1 | Isolation of bioactive compound(s) by preparative TLC | 71 |
| 4.21.2 | Characterization of purified bioactive compound | 71 |
| 4.21.2.1 | HPTLC Fingerprinting | 71 |
| 4.21.2.2 | FT-IR analysis | 71 |
| Chapter : 5 | Result and Discussion | 72 |
| 5.1 | Preliminary phytochemical screening of crude extracts | 72 |
| 5.2 | Phytochemical Analysis of Crude Extract | 73 |
| 5.3 | Result of Total phenolic content of crude extract | 75 |
| 5.4 | Result of Total flavonoid content of crude extract | 76 |
| 5.5 | Result of Total antioxidant capacity of crude Extract | 78 |
| 5.6 | <i>In-vitro</i> anticoagulant activity of crude extracts | 79 |
| 5.6.1 | Blood clotting time measurement | 79 |
| 5.6.2 | Prothrombin time (PT) activity assay | 81 |
| 5.6.3 | Activated Partial Thromboplastin time (APTT) activity assay | 82 |
| 5.7 | Preliminary phytochemical screening of Fractions | 84 |
| 5.7.1 | Preliminary Phytochemical Screening of <i>C.medica</i> Fractions | 84 |
| 5.7.2 | Preliminary Phytochemical Screening of <i>T.undulata</i> Fractions | 85 |
| 5.8 | Result of Total phenolic content of fractions | 86 |

| | | |
|----------|--|-----|
| 5.8.1 | Result of total phenolic content of fraction of <i>C.medica</i> | 86 |
| 5.8.2 | Result of total phenolic content of fraction of <i>T.undulata</i> | 87 |
| 5.9 | Result of Total flavonoid content of fractions | 89 |
| 5.9.1 | Result of total flavonoid content of fraction of <i>C.medica</i> | 89 |
| 5.9.2 | Result of total flavonoid content of fraction of <i>T.undulata</i> | 90 |
| 5.10 | Result of Total antioxidant capacity of fractions | 91 |
| 5.10.1 | Result of total antioxidant capacity of a fraction of <i>C.medica</i> | 91 |
| 5.10.2 | Result of total antioxidant capacity of a fraction of <i>T.undulata</i> | 92 |
| 5.11 | <i>In-vitro</i> antioxidant activity of fractions | 93 |
| 5.11.1 | DPPH free radical scavenging activity | 93 |
| 5.11.1.1 | DPPH free radical scavenging activity of fractions of <i>C.medica</i> | 93 |
| 5.11.1.2 | DPPH free radical scavenging activity of fractions of <i>T.undulata</i> | 95 |
| 5.11.2 | Superoxide radical scavenging activity | 97 |
| 5.11.2.1 | Superoxide radical scavenging activity of fractions of <i>C.medica</i> | 97 |
| 5.11.2.2 | Superoxide radical scavenging activity of fractions of <i>T.undulata</i> | 97 |
| 5.11.3 | Nitric oxide radical scavenging activity | 98 |
| 5.11.3.1 | Nitric oxide radical scavenging activity of fractions of <i>C.medica</i> | 98 |
| 5.11.3.2 | Nitric oxide radical scavenging activity of fractions of <i>T.undulata</i> | 98 |
| 5.11.4 | Metal ion (Ferric ion) chelating activity: | 99 |
| 5.11.4.1 | Metal ion (Ferric ion) chelating activity of fractions of <i>C.medica</i> | 99 |
| 5.11.4.2 | Metal ion (Ferric ion) chelating activity of fractions of <i>T.undulata</i> | 100 |
| 5.11.5 | Reducing Power Capacity Activity | 101 |

| | | |
|----------|--|-----|
| 5.11.5.1 | Reducing the power capacity of the fraction of <i>C. medica</i> | 101 |
| 5.11.5.2 | Reducing the power capacity of the fraction of <i>T.undulata</i> | 101 |
| 5.12 | <i>In-vitro</i> anticoagulant activity of fractions | 102 |
| 5.12.1 | Blood clotting time measurement | 102 |
| 5.12.1.1 | Blood clotting time measurement of fractions of <i>C.medica</i> | 102 |
| 5.12.1.2 | Blood clotting time measurement of fractions of <i>T.undulata</i> | 103 |
| 5.12.2 | Prothrombin time (PT) activity assay | 105 |
| 5.12.2.1 | Prothrombin time measurement of fractions of <i>C.medica</i> | 105 |
| 5.12.2.2 | Prothrombin time measurement of fractions of <i>T.undulata</i> | 107 |
| 5.12.3 | Activated Partial Thromboplastin time (APTT) activity assay | 108 |
| 5.12.3.1 | Activated Partial Thromboplastin time measurement of fractions of <i>C.medica</i> | 108 |
| 5.12.3.2 | Activated Partial Thromboplastin time measurement of fractions of <i>T.undulata</i> | 110 |
| 5.13 | Qualitative HPTLC Fingerprinting: | 112 |
| 5.13.1 | Qualitative HPTLC Fingerprinting of fractions of <i>C.medica</i> | 113 |
| 5.13.2 | Qualitative HPTLC Fingerprinting of fractions of <i>T.undulata</i> | 116 |
| 5.14 | <i>In-vivo</i> anticoagulant activity of Fractions | 119 |
| 5.14.1 | <i>In-vivo</i> Blood Clotting Time Measurement | 119 |
| 5.14.1.1 | <i>In-vivo</i> Blood clotting time measurement of ethyl acetate fraction of <i>C.medica</i> | 119 |
| 5.14.1.2 | <i>In-vivo</i> Blood clotting time measurement of butanol fraction of <i>T.undulata</i> | 120 |
| 5.14.2 | <i>In-vivo</i> Prothrombin time (PT) activity assay | 122 |

| | | |
|--------------------|---|------------|
| 5.14.2.1 | <i>In-vivo</i> Prothrombin time measurement of ethyl acetate fraction of <i>C.medica</i> | 122 |
| 5.14.2.2 | <i>In-vivo</i> Prothrombin time measurement of butanol fraction of <i>T.undulata</i> | 123 |
| 5.14.3 | <i>In-vivo</i> Activated Partial Thromboplastin time (APTT) activity assay | 124 |
| 5.14.3.1 | <i>In-vivo</i> Activated Partial Thromboplastin time measurement of ethyl acetate fraction of <i>C.medica</i> | 124 |
| 5.14.3.2 | <i>In-vivo</i> Activated Partial Thromboplastin time measurement of butanol fraction of <i>T.undulata</i> | 126 |
| 5.15 | GC-MS Analysis | 129 |
| 5.15.1 | GCMA Analysis of ethyl acetate fraction of <i>C.medica</i> | 129 |
| 5.15.2 | GCMA Analysis of ethyl acetate fraction of <i>T.undulata</i> | 140 |
| 5.16 | LCMS/MS Analysis | 147 |
| 5.16.1 | LCMS/MS analysis of ethyl acetate fraction of <i>C.medica</i> | 147 |
| 5.17 | Isolation and Characterization of Bioactive Compound from ethyl acetate fraction of <i>Citrus medica</i> | 149 |
| 5.17.1 | Isolation of bioactive compound from ethyl acetate fraction of <i>C.medica</i> | 149 |
| 5.17.2 | Characterization of bioactive compound from ethyl acetate fraction of <i>C.medica</i> | 150 |
| 5.17.2.1 | HPTLC analysis | 150 |
| 5.17.2.2 | FTIR analysis | 153 |
| Chapter : 6 | Summary and Conclusion | 155 |
| Chapter: 7 | Bibliography | 157 |
| Appendices | | 192 |
| Appendix A | Plagiarism Report | 192 |
| Appendix B | Publication | 194 |
| Appendix C | IAEC Certificate | 197 |
| Appendix D | Plant Authentication Certificate | 199 |

List of Figures

| Figure No. | Name of the Figure | Pg. No. |
|--------------------|--|---------|
| Figure 1.1 | 1a) Incidence rate 1b) Mortality rate of thrombotic diseases | 4 |
| Figure 2.1 | Blood clotting cascade | 10 |
| Figure 2.2 | Virchow's triad | 12 |
| Figure 4.1 | Bark of <i>Tecomella undulata</i> | 38 |
| Figure 4.2 | Fruit of <i>Citrus medica</i> | 38 |
| Figure 4.3 | Seed of <i>Sesame indicum</i> | 38 |
| Figure 4.4 | Schematic representation of modified Kupachan partitioning | 53 |
| Figure 5.1 | Chromatogram of the solvent residue of <i>C.medica</i> methanolic extract | 74 |
| Figure 5.2 | Chromatogram of the solvent residue of <i>T.undulata</i> methanolic extract | 75 |
| Figure 5.3 | Chromatogram of the solvent residue of <i>S.indicum</i> methanolic extract | 75 |
| Figure 5.4 | A) Total phenolic content of crude extracts B) Calibration curve of Gallic acid | 76 |
| Figure 5.5 | A) Total flavonoid content of crude extracts B) Calibration curve of Quercetin | 77 |
| Figure 5.6 | A) Total Antioxidant capacity of crude extracts B) Calibration curve of Ascorbic acid | 78 |
| Figure 5.7 | <i>In-vitro</i> Blood clotting time of Crude extracts varying concentration of Crude extracts | 80 |
| Figure 5.8 | <i>In-vitro</i> Blood clotting time of Crude extracts at 100, 200, and 500 mg/ml concentration | 80 |
| Figure 5.9 | <i>In-vitro</i> Prothrombin time of Crude extracts | 82 |
| Figure 5.10 | <i>In-vitro</i> Activated Partial Thromboplastin time of Crude extracts. | 82 |
| Figure 5.11 | A) Total phenolic content of fraction of <i>C.medica</i> B) Calibration curve of Gallic acid | 86 |
| Figure 5.12 | A) Total phenolic content of fraction of <i>T.undulata</i> B) Calibration curve of Gallic acid | 87 |

| | | |
|--------------------|---|-----|
| Figure 5.13 | A) Total flavonoid content of fraction of <i>C.medica</i> B) Calibration curve of quercetin | 89 |
| Figure 5.14 | A) Total flavonoid content of fraction of <i>T.undulata</i> B) Calibration curve of quercetin | 90 |
| Figure 5.15 | A) Total antioxidant capacity of a fraction of <i>C.medica</i> B) Calibration curve of ascorbic acid | 91 |
| Figure 5.16 | A) Total antioxidant capacity of a fraction of <i>T.undulata</i> B) Calibration curve of ascorbic acid | 92 |
| Figure 5.17 | A) DPPH B) Superoxide C) Nitric oxide D) Ferric ion activity of <i>C.medica</i> fractions | 95 |
| Figure 5.18 | A) DPPH B) Superoxide C) Nitric oxide D) Ferric ion activity of <i>T.undulata</i> fractions | 96 |
| Figure 5.19 | Reducing power capacity of A) <i>C.medica</i> B) <i>T.undulata</i> fractions | 101 |
| Figure 5.20 | <i>In-vitro</i> blood clotting time of varying concentration of fractions of <i>C.medica</i> | 102 |
| Figure 5.21 | <i>In-vitro</i> blood clotting time of fractions of <i>C.medica</i> at 2.5, 5, 7.5, and 10 mg/ml | 103 |
| Figure 5.22 | <i>In-vitro</i> blood clotting time of varying concentrations of fractions of <i>T.undulata</i> | 104 |
| Figure 5.23 | <i>In-vitro</i> blood clotting time of fractions of <i>T.undulata</i> at 2.5, 5, 7.5, and 10 mg/ml | 105 |
| Figure 5.24 | <i>In-vitro</i> prothrombin time of fractions of <i>C.medica</i> | 106 |
| Figure 5.25 | <i>In-vitro</i> Prothrombin time of fractions of <i>T.undulata</i> | 107 |
| Figure 5.26 | <i>In-vitro</i> Activated Partial Thromboplastin time of fractions of <i>C.medica</i> | 109 |
| Figure 5.27 | <i>In-vitro</i> Activated Partial Thromboplastin time of fractions of <i>T.undulata</i> | 110 |
| Figure 5.28 | HPTLC fingerprinting of fractions of <i>citrus medica</i> A) At 366 nm B) 254 nm | 113 |
| Figure 5.29 | A) 3D chromatogram of fractions of <i>C.medica</i> B) chromatogram of CMEAF | 114 |
| Figure 5.30 | Chromatogram of A) CMBUF B) CMPEF | 114 |

| | | |
|--------------------|---|-----|
| Figure 5.31 | Chromatogram of A) CMBF B) CMWF | 114 |
| Figure 5.32 | HPTLC fingerprinting of fractions of <i>citrus medica</i> A) At 366 nm B) 254 nm | 116 |
| Figure 5.33 | A) 3D chromatogram of fractions of <i>T.undulata</i> B) chromatogram of TUEAF | 117 |
| Figure 5.34 | Chromatogram of A) TUBUF B) TUPEF | 117 |
| Figure 5.35 | Chromatogram of A) TUBF B) TUWF | 117 |
| Figure 5.36 | <i>In-vivo</i> Blood clotting time of ethyl acetate fraction of <i>C.medica</i> | 120 |
| Figure 5.37 | <i>In-vivo</i> Blood clotting time of butanol fraction of <i>T.undulata</i> | 121 |
| Figure 5.38 | <i>In-vivo</i> Prothrombin time of ethyl acetate fraction of <i>C.medica</i> | 123 |
| Figure 5.39 | <i>In-vivo</i> Prothrombin time of butanol fraction of <i>T.undulata</i> | 124 |
| Figure 5.40 | <i>In-vivo</i> Activated Partial Thromboplastin time of ethyl acetate fraction of <i>C.medica</i> | 125 |
| Figure 5.41 | <i>In-vivo</i> Activated Partial Thromboplastin time of butanol fraction of <i>T.undulata</i> | 127 |
| Figure 5.42 | GC-MS chromatogram of ethyl acetate fraction of <i>C.medica</i> | 130 |
| Figure 5.43 | Mass fragmentation pattern of peak 1 of CMEAF | 135 |
| Figure 5.44 | Mass fragmentation pattern of peak 2 of CMEAF | 136 |
| Figure 5.45 | Mass fragmentation pattern of peak 3 of CMEAF | 136 |
| Figure 5.46 | Mass fragmentation pattern of peak 4 of CMEAF | 136 |
| Figure 5.47 | Mass fragmentation pattern of peak 5 of CMEAF | 136 |
| Figure 5.48 | Mass fragmentation pattern of peak 6 of CMEAF | 137 |
| Figure 5.49 | Mass fragmentation pattern of peak 7 of CMEAF | 137 |
| Figure 5.50 | Mass fragmentation pattern of peak 8 of CMEAF | 137 |
| Figure 5.51 | Mass fragmentation pattern of peak 9 of CMEAF | 137 |
| Figure 5.52 | Mass fragmentation pattern of peak 10 of CMEAF | 138 |
| Figure 5.53 | Mass fragmentation pattern of peak 11 of CMEAF | 138 |
| Figure 5.54 | Mass fragmentation pattern of peak 12 of CMEAF | 138 |
| Figure 5.55 | Mass fragmentation pattern of peak 13 of CMEAF | 138 |
| Figure 5.56 | Mass fragmentation pattern of peak 14 of CMEAF | 139 |
| Figure 5.57 | Mass fragmentation pattern of peak 15 of CMEAF | 139 |
| Figure 5.58 | GC-MS chromatogram of butanol fraction of <i>T.undulata</i> | 140 |
| Figure 5.59 | Mass fragmentation pattern of peak 1 of TUBUF | 144 |

| | | |
|--------------------|--|-----|
| Figure 5.60 | Mass fragmentation pattern of peak 2 of TUBUF | 144 |
| Figure 5.61 | Mass fragmentation pattern of peak 3 of TUBUF | 144 |
| Figure 5.62 | Mass fragmentation pattern of peak 4 of TUBUF | 144 |
| Figure 5.63 | Mass fragmentation pattern of peak 5 of TUBUF | 145 |
| Figure 5.64 | Mass fragmentation pattern of peak 6 of TUBUF | 145 |
| Figure 5.65 | Mass fragmentation pattern of peak 7 of TUBUF | 145 |
| Figure 5.66 | Mass fragmentation pattern of peak 8 of TUBUF | 145 |
| Figure 5.67 | Mass fragmentation pattern of peak 9 of TUBUF | 146 |
| Figure 5.68 | Mass fragmentation pattern of peak 10 of TUBUF | 146 |
| Figure 5.69 | Representative MRM chromatograms of rutin (A), quercetin (B), gallic acid (C) | 148 |
| Figure 5.70 | MS Calibration Curve of A) Gallic Acid B) Quercetin C) Rutin | 148 |
| Figure 5.71 | HPTLC of Ethyl acetate fraction of <i>C.medica</i> A) at 254 nm B) at 365 nm | 149 |
| Figure 5.72 | HPTLC of isolated compounds from CMEAF and ferulic acid A) at 254 nm B) at 365 nm | 151 |
| Figure 5.73 | 3D chromatogram of isolated compounds from CMEAF and ferulic acid | 151 |
| Figure 5.74 | Chromatogram of isolated compound 1 from CMEAF | 152 |
| Figure 5.75 | Chromatogram of isolated compound 2 from CMEAF | 152 |
| Figure 5.76 | Chromatogram of isolated compound 3 from CMEAF | 152 |
| Figure 5.77 | Chromatogram of Ferulic acid standard | 153 |
| Figure 5.78 | FTIR of isolated compound 1 from ethyl acetate fraction of <i>C.medica</i> | 154 |

List of Tables

| Table No. | Name of Table | Pg. No. |
|------------------|--|---------|
| Table 2.1 | Classification of drugs | 15 |
| Table 2.2 | Phytochemical Review of <i>Tecomella undulata</i> | 17 |
| Table 2.3 | Pharmacological Review of <i>Tecomella undulata</i> | 19 |
| Table 2.4 | Phytochemical Review of <i>Citrus medica</i> | 23 |
| Table 2.5 | Pharmacological Review of <i>Citrus medica</i> | 26 |
| Table 2.6 | Phytochemical Review of <i>Sesame indicum</i> | 30 |
| Table 2.7 | Pharmacological Review of <i>Sesame indicum</i> | 32 |
| Table 2.8 | List of plants with anticoagulant activity | 34 |
| Table 4.1 | Parameters of GC-MS and Headspace for Solvent Residue Analysis | 47 |
| Table 4.2 | Optimization of Chromatographic condition | 60 |
| Table 4.3 | Detail Experimental design method | 63 |
| Table 4.4 | Optimization parameter of GC-MS | 65 |
| Table 4.5 | Spiking solution of standards for the calibration curve | 68 |
| Table 4.6 | LC-MS/MS instrumentation | 68 |
| Table 4.7 | Tuning Parameter of MS/MS for drug and internal standard and source dependant parameter | 69 |
| Table 4.8 | Chromatographic Conditions | 70 |
| Table 5.1 | Yield (%) and phytochemical screening of crude extract of <i>Tecomella undulata</i> bark, <i>Citrus medica</i> fruit, and <i>Sesame indicum</i> seed | 72 |
| Table 5.2 | Phytochemical analysis of a crude extract of <i>Tecomella undulata</i> bark, <i>Citrus medica</i> fruit, and <i>Sesame indicum</i> seed | 73 |
| Table 5.3 | Total Phenolic content of crude extracts | 76 |
| Table 5.4 | Total Flavonoid content of crude extracts | 77 |
| Table 5.5 | Total Antioxidant capacity of crude extracts | 78 |
| Table 5.6 | <i>In-vitro</i> clotting time of varying concentrations of crude extracts | 79 |
| Table 5.7 | <i>In-vitro</i> prothrombin time (PT) and Activated prothrombin time (APTT) of crude extracts | 81 |
| Table 5.8 | Yield (%) and phytochemical screening of fractions of <i>Citrus medica</i> fruit | 84 |

| | | |
|-------------------|--|-----|
| Table 5.9 | Yield (%) and phytochemical screening of fractions of <i>Tecomella undulata</i> bark | 85 |
| Table 5.10 | Total Phenolic content of fractions of <i>Citrus medica</i> fruit | 87 |
| Table 5.11 | Total Phenolic content of fractions of <i>T.undulata</i> bark | 87 |
| Table 5.12 | Total flavonoid content of fractions of <i>Citrus medica</i> fruit | 89 |
| Table 5.13 | Total flavonoid content of fractions of <i>Tecomella undulata</i> bark | 90 |
| Table 5.14 | Total antioxidant capacity of fractions of <i>Citrus medica</i> fruit | 91 |
| Table 5.15 | Total antioxidant capacity of fractions of <i>Tecomella undulata</i> bark | 92 |
| Table 5.16 | IC ₅₀ values of fractions of <i>C.medica</i> fruit on different <i>in vitro</i> antioxidant activity | 94 |
| Table 5.17 | IC ₅₀ values of fractions of <i>T.undulata</i> bark on different <i>in vitro</i> antioxidant activity | 96 |
| Table 5.18 | <i>In-vitro</i> blood clotting time of fractions of <i>C.medica</i> | 103 |
| Table 5.19 | <i>In-vitro</i> blood clotting time of fractions of <i>T.undulata</i> | 105 |
| Table 5.20 | <i>In-vitro</i> prothrombin time of fractions of <i>C.medica</i> | 106 |
| Table 5.21 | <i>In-vitro</i> prothrombin time of fractions of <i>T.undulata</i> | 108 |
| Table 5.22 | <i>In-vitro</i> Activated Partial Thromboplastin time of fractions of <i>C.medica</i> | 109 |
| Table 5.23 | <i>In-vitro</i> Activated Partial Thromboplastin time of fractions of <i>T.undulata</i> | 111 |
| Table 5.24 | HPTLC fingerprinting analysis of fractions of <i>C.medica</i> | 113 |
| Table 5.25 | Number of bands, Rf value, and percentage of peak area of various fractions of <i>C.medica</i> | 111 |
| Table 5.26 | HPTLC fingerprinting analysis of fractions of <i>T.undulata</i> | 115 |
| Table 5.27 | Number of bands, Rf value, and percentage of peak area of various fractions of <i>T.undulata</i> | 118 |
| Table 5.28 | <i>In-vivo</i> Blood clotting time of ethyl acetate fraction of <i>C.medica</i> | 119 |
| Table 5.29 | <i>In-vivo</i> Blood clotting time of butanol fraction of <i>T.undulata</i> | 121 |
| Table 5.30 | <i>In-vivo</i> Prothrombin time of ethyl acetate fraction of <i>C.medica</i> | 122 |
| Table 5.31 | <i>In-vivo</i> Prothrombin time of butanol fraction of <i>T.undulata</i> | 123 |
| Table 5.32 | <i>In-vivo</i> Activated Partial Thromboplastin time of ethyl acetate fraction of <i>C.medica</i> | 125 |

| | | |
|-------------------|---|-----|
| Table 5.33 | <i>In-vivo</i> Activated Partial Thromboplastin time of butanol fraction of <i>T.undulata</i> | 126 |
| Table 5.34 | Retention time, peak area, name of compound present in CMEAF | 130 |
| Table 5.35 | Retention time, peak area, name of compound present in TUBUF | 141 |
| Table 5.36 | The calibration curves, linear ranges, and LLOQs of the rutin, quercetin, and gallic acid | 149 |
| Table 5.37 | Rf value and percentage peak area of ethyl acetate of <i>C.medica</i> | 150 |
| Table 5.38 | Rf value and percentage peak area of isolated compounds from CMEAF and ferulic acid | 150 |

List of Abbreviation and Symbol

| Abbreviation | Definition |
|-------------------|---|
| ADP | Adenosine diphosphate |
| AF | Atrial fibrillation |
| AF | Aqueous fraction |
| AIDS | Acquired immunodeficiency syndrome |
| AlCl ₃ | Aluminum chloride |
| ANOVA | Analysis of variance |
| APTT | Activated Partial Thromboplastin Time |
| BF | Benzene fraction |
| BUF | Butanol fraction |
| CaCl ₂ | Calcium Chloride |
| CAD | Coronary artery disease |
| CC | Calibration Curve |
| CCSEA | Committee for Control and Supervision of Experiments on Animals |
| CDK7 | Cyclin dependent kinase 7 |
| CMBF | <i>Citrus medica</i> benzene ether fraction |
| CMBUF | <i>Citrus medica</i> butanol fraction |
| CMEAF | <i>Citrus medica</i> ethyl acetate fraction |
| CMME | <i>Citrus medica</i> methanolic extract |
| CMPEF | <i>Citrus medica</i> Petroleum ether fraction |
| CMWF | <i>Citrus medica</i> water fraction |
| CT | Clotting Time |
| CuSO ₄ | Copper (II) sulfate |
| DPPH | 1, 1-Diphenyl-2-Picrylhydrazyl |
| DRSA | DPPH radical scavenging activity |
| DVT | deep vein thrombosis |
| EAF | Ethyl acetate fraction |
| EDTA | Ethylenediaminetetraacetic acid |
| Factor I | Fibrinogen |
| Factor II | Prothrombin |
| Factor III | Tissue thromboplastin (tissue factor) |

| | |
|------------------------------------|---|
| Factor IV | Ionized calcium (Ca ⁺⁺) |
| Factor IX | Plasma thromboplastin component, Christmas factor |
| Factor V | Labile factor or proaccelerin. |
| Factor VI | Unassigned. |
| Factor VII | Stable factor or proconvertin. |
| Factor VIII | Antihemophilic factor |
| Factor X | Stuart-Prowar factor |
| Factor XI | Plasma thromboplastin antecedent |
| Factor XII | Hageman factor |
| Factor XIII | Fibrin-stabilizing factor |
| FeCl ₃ | Ferric Chloride |
| FTIR | Fourier Transform Infrared Spectroscopy |
| GAE | Gallic acid equivalents |
| GCMS | Gas Chromatography-Mass Spectrometry |
| H ₂ SO ₄ | Sulphuric acid |
| HCL | Hydrochloric acid |
| HDL-C | High-density lipoprotein cholesterol |
| HIV | Human immunodeficiency virus |
| HPLC | High Performance Liquid Chromatography |
| HPTLC | High-performance thin-layer chromatography |
| IAEC | Institutional Animal Ethical Committee |
| IC ₅₀ | Half-maximal inhibitory concentration |
| ICH | International Council for Harmonization |
| IR | Infrared spectroscopy |
| K ₃ Fe(CN) ₆ | Potassium ferricyanide |
| KOH | Potassium hydroxide |
| LCMS | Liquid chromatography-mass spectrometry |
| LDL-C | Low-density lipoprotein cholesterol |
| MI | Myocardial infarction |
| MRM | Multiple reaction monitoring |
| MS | Mass spectrometry |
| NaCl | Sodium Chloride |
| NaCN | Sodium cyanide |

| | |
|-------|---|
| NaOH | Sodium hydroxide |
| NBT | Nitro blue tetrazolium |
| NBT2+ | Nitro-blue tetrazolium formazan |
| NEDD | Naphthyl ethylenediamine |
| NIST | National Institute of Standard and Technology |
| NO | Nitric oxide |
| NOACs | New or novel oral anticoagulants |
| NS | Normal Saline |
| NS | Normal saline |
| PAF | Platelet-activating factor |
| PBS | Phosphate buffer saline |
| PE | Pulmonary embolism |
| PEF | Petroleum ether fraction |
| PEG | Polyethylene glycol |
| PPP | Platelet poor plasma |
| PT | Prothrombin Time |
| QAE | Quercetin equivalents |
| QUE | Quercetin Equivalent |
| Rf | Retention factor |
| SD | Standard deviation |
| SEM | Standard error of the mean |
| SIME | <i>Sesamum indicum</i> methanolic extract |
| SK | Streptokinase |
| TAC | Total Antioxidant Activity |
| TAE | Tannic acid equivalents |
| TCA | Trichloroacetic acid |
| TE | Thrombotic encephalopathy |
| TF | Tissue factor |
| TFC | Total Flavonoid content |
| TLC | Thin-layer chromatography |
| tPA | Tissue plasminogen activator |
| TPC | Total phenolic content |
| TT | thrombin time |

| | |
|---------------------|--|
| TUBF | <i>Tecomella undulate</i> benzene ether fraction |
| TUBUF | <i>Tecomella undulate</i> butanol fraction |
| TUEAF | <i>Tecomella undulate</i> ethyl acetate fraction |
| TUME | <i>Tecomella undulata</i> methanolic extract |
| TUPEF | <i>Tecomella undulate</i> Petroleum ether fraction |
| TUWF | <i>Tecomella undulate</i> water fraction |
| UK | Urokinase |
| VTE | Venous thromboembolism |
| WHO | The World Health Organization |
| α | p<0.05 significant when compared with Normal saline |
| β | p<0.01 significant when compared with Normal saline |
| γ | p<0.001 significant when compared with Normal saline |
| + | <i>POSITIVE</i> |
| - | <i>NEGATIVE</i> |
| #p<0.001 | Highly significant |
| * <i>P<0.05</i> | Significant |
| ** <i>P<0.01</i> | Very significant |
